EPRX (Eupraxia Pharmaceuticals) ROE % Adjusted to Book Value : -19.82% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals ROE % Adjusted to Book Value?

Eupraxia Pharmaceuticals's ROE % for the quarter that ended in Sep. 2024 was -195.24%. Eupraxia Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2024 was 9.85. Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -19.82%.

Eupraxia Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals ROE % Adjusted to Book Value Chart

Eupraxia Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-20.88

-10.98

Eupraxia Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-17.34	-10.79	-37.66	-22.55	-19.82

Competitive Comparison of Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Eupraxia Pharmaceuticals ROE % Adjusted to Book Value Calculation

Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-564.25%	/	51.37
	=	-10.98%

Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-195.24%	/	9.85
	=	-19.82%

Eupraxia Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

EPRX:Canada

Address

201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4

Website

https://www.eupraxiapharma.com

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.